|Bid||76.00 x 800|
|Ask||77.91 x 1100|
|Day's range||75.80 - 77.99|
|52-week range||57.17 - 89.74|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||17.62|
|Forward dividend & yield||3.00 (3.94%)|
|Ex-dividend date||14 Jun 2023|
|1y target est||N/A|
Three Motley Fool contributors identified dividend stocks that should be easy buy decisions for investors. Here's why they think Bristol Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are investments you can make in June without any hesitation. David Jagielski (Bristol Myers Squibb): Bristol Myers Squibb has been paying dividends for more than 90 consecutive years.
Gilead Sciences, Inc.'s ( NASDAQ:GILD ) dividend will be increasing from last year's payment of the same period to...
Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...
Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now.
Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.
You may know of Gilead Sciences (NASDAQ: GILD) because of its blockbuster coronavirus treatment Veklury. In fact, the S&P 500 has outperformed Gilead over the past five years. Gilead has struggled to consistently deliver annual revenue growth ever since its hepatitis C portfolio's revenue reached a peak back in 2015.
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Let's look at two great dividend stocks to consider buying before the economy worsens: Gilead Sciences (NASDAQ: GILD) and Amgen (NASDAQ: AMGN). Gilead Sciences is a biotech company with a particular focus on developing HIV medicines. It has helped Gilead Sciences' revenue stay afloat as the company failed to earn approval for important candidates.
Gilead Sciences (NASDAQ: GILD) has a bright future ahead with HIV treatment Sunlenca obtaining approval from the Food and Drug Administration last year and cancer drug Trodelvy continuing to show strong growth. Why has Gilead Sciences stock struggled? The simple reason for Gilead's woes is that the business has had trouble generating growth.
Gilead Sciences, Inc. ( NASDAQ:GILD ) will increase its dividend from last year's comparable payment on the 29th of...
If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly...
Jacquie, please go ahead. The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey; and our chief financial officer, Andrew Dickinson.
Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.
Gilead (GILD) delivered earnings and revenue surprises of -15.95% and 0.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Two great examples are Pfizer (NYSE: PFE) and Gilead Sciences (NASDAQ: GILD). Pfizer is facing two challenges right now. First, demand for its coronavirus vaccine and treatment is falling as we move toward a post-pandemic situation.
Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
With that in mind, let's look at two dividend-paying companies whose shares are trading for less than $100 right now: Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE). The past three years have been an up-and-down battle for Gilead Sciences. Filgotinib was supposed to be Gilead Sciences' next blockbuster, so this was a blow for the company.
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
In the latest trading session, Gilead Sciences (GILD) closed at $83.78, marking a +0.18% move from the previous day.